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Aims: A cross-sectional multicenter study was designed to assess health-related quality of life
(HRQL) in women with chronic obstructive pulmonary disease (COPD) who were attended in
the outpatient setting in actual conditions of the daily practice.
Methods: A total of 1786 women with COPD (mean age of 66.5 years) and 1661 pairs of men and
women matched by age and COPD severity participated in a cross-sectional study. HRQL was
measured with the Short Form 12 Health Survey Questionnaire (SF-12).
Results: The mean PCS-12 and MCS-12 scores were 36.5 10.3 and 44.1 11.8, respectively.
General health and physical functioning domains were those with the lowest scores, whereas
role emotional and social functioning were those with the highest scores. The percentage of
women with low HRQL increased according to age, whereas the percentage of women with
high or normal HRQL decreased significantly. In relation to COPD severity, more women rated
HRQL as low in the physical component than in the mental component. HRQL correlated signif-
icantly with FEV1 in both PCS-12 and MCS-12 scales. As expected, an inverse significant corre-
lation between HRQL and degree of dyspnea in the PCS-12 and the MCS-12 scales was observed.
Women had also a significantly worse HRQL than men in all physical and mental domains.
Conclusions: In outpatient women with COPD, HRQL was impaired especially the physical
component of the SF-12. For the same age and severity of COPD, women showed significantly
lower scores in all physical and mental domains of the SF-12 than men.
ª 2009 Elsevier Ltd. All rights reserved.al Congress of the European Respiratory Society, Stockholm, Sweden, September 18, 2007.
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Chronic obstructive pulmonary disease (COPD) is a major
cause of chronic morbidity and mortality and represents
a substantial economic and social burden throughout the
world.1,2 Smoking is the most common cause of COPD. From
a historical perspective, COPD has been considered to occur
more frequently in men than in women, which has been
largely attributed to the differences in smoking rates.3,4 In
recent years, however, COPD has become an increasing
problem among women. In the United States, the absolute
numbers of COPD cases, hospitalizations, and deaths among
women have surpassed the number of men,5 and similar
trends have been observed in other Western countries.6e8
This has occurred despite evidence of gender bias in the
diagnosis of COPD.9,10
The increasing prevalence of COPD among women is
thought to be related to the secular trends in smoking
habits,11 although some authors have suggested that
women may be more susceptible to the damaging effects of
tobacco than men.12e14 The concept of differential
susceptibility remains controversial,15 but it is becoming
clear that there are important differences between men
and women in the development, progression, and outcomes
of COPD.16e19 Moreover, the physiologic changes of COPD
affect women and men differently in terms of symptoms
and quality of life. Women with COPD also demonstrate
higher levels of anxiety and depression than their male
counterparts.20,21
Health-related quality of life (HRQL) has received an
increasing interest over the past decade as an important
measurable outcome in patients with COPD. An impaired
health status is an important determinant to predict
mortality,22 exacerbations and hospital admissions,23 and
response to different treatment options.24 Previous studies
using both generic and disease-specific instruments for
measuring HRQL in COPD patients25 have shown relation-
ships between HRQL and disease severity, respiratory
symptoms, gender, comorbidity, body weight, upper airway
symptoms and psychological status.26e31 In a recent study
carried out in Spain, determinants of HRQL in patients with
COPD who were followed in primary care included sex,
forced expiratory volume in 1 s (FEV1), use of oxygen
therapy, and number of visits to emergency rooms and
hospital admissions.32 However, there are only a few studies
on HRQL in female populations with COPD.18 In a case series
of 53 FEV1-matched men and women with COPD, de Torres
et al.17 found that women had worse scores in the Saint
George’s Respiratory Questionnaire (SGRQ) than men at
younger age and earlier stage of the disease.17 In a separate
series of 146 FEV1-matched men and women with COPD, the
same authors, reported that, compared with men, women
also had worse scores in all domains of the SGRQ. Thus for
a similar degree of physiological impairment, women
experienced more severe dyspnea and worse health
status.33 Furthermore, the factors that determine HRQL for
men and women with COPD may differ by gender.
To further contribute to the characterization of HRQL in
female patients with COPD, a multicenter cross-sectional
study was designed, the primary objectives of which were to
assess HRQL in a large sample of womenwith COPDwhowereattended in the outpatient setting in actual conditions of the
daily practice, and to examine differences in HRQL between
men and women matched by age and severity of COPD.
Materials and methods
Patient population
We conducted a 2-month cross-sectional survey of the first
five consecutive patients with COPD who were visited by
general practitioners in primary care centers and by
pneumologists in the outpatient clinics of the Services of
Pneumology of acute-care hospitals from all over the
country in Spain. A sample of 2300 general practitioners
and 200 pneumologists were recruited using a stratified
random sample drawn from the list of registered physicians
in all autonomous communities.
Patients of both the sexes, aged 40 years or older, with
a previous diagnosis of COPD (confirmed by history and
spirometry) were eligible provided the reason of consulta-
tion was related to his/her pulmonary condition. The
diagnosis of the disease was performed according to the
criteria of the Spanish Society of Pneumology and Chest
Surgery (SEPAR) based on the demonstration, through
a forced spirometry, of an FEV1 below 80% of the reference
value and an FEV1/forced vital capacity (FVC) ratio below
0.7 after the bronchodilation test. The severity of COPD
was rated at three levels according to the FEV1 value: mild
(FEV1 60e80% of the reference value), moderate (FEV1
40e59% of the reference value) and severe (FEV1< 40% of
the reference value) following SEPAR criteria,34 which are
based on the guidelines of the British Thoracic Society.35
Spirometric measurements at the time of the study were
not performed. Patients with an acute worsening of their
COPD in the previous month were excluded as were those
suffering from any physical and/or psychiatric disease
precluding to complete the HRQL questionnaire. Patients
with more than 80% of missing data for the study variables
in their medical records were also excluded.
For the purpose of the present study, the MUVICE Study
(Spanish acronym of Women Living with Chronic Obstruc-
tive Pulmonary Disease), the cohort of women was
selected, as well as an equal number of men with COPD
matched by age and severity of COPD measured by FEV1.
The main objectives of the study were to assess HRQL in the
MUVICE cohort and to determine differences in HRQL
between men and women matched by age and severity of
COPD as measured by the FEV1. Secondary objectives
included to assess the correlation between HRQL and FEV1
and dyspnea in women, to gather information on the
treatment of COPD in women, and to assess gender-related
differences in health resources utilization.
The study protocol was approved by the Ethics
Committee of hospital Gregorio Maran˜o´n, Madrid (Spain),
and written informed consent was obtained from all the
participants.
Procedures and data collection
Interviews were carried out by the participating physician
in the course of the patient’s consultation in routine daily
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a questionnaire in which the following variables were
recorded: age; sex; height; weight; smoking habit (current
smoker, never smoker, ex-smoker); year of COPD diagnosis;
data of the last spirometric measurement and FEV1 and
FEV1/FVC values; severity of COPD; current COPD therapy
including non-pharmacological management (smoking
cessation counseling, stop smoking treatment, oxygen
therapy, rehabilitation, others) and pharmacological
treatment (short-acting b2 agonists, long-acting b2 agonists,
short-acting anticholinergics, long-acting anticholinergics,
inhaled steroids, oral steroids, a fixed combination of
anticholinergics and short-acting b2 agonists, a fixed
combination of long-acting b2 agonists and inhaled steroids,
antibiotics, others); disability; and health resources utili-
zation in the previous 12 months (number of outpatient
visits to either the primary care physician or the pneu-
mologist, emergency department visits, hospitalizations,
and days on sick leave).
Disability was classified according to the Medical
Research Council (MRC) dyspnea scale.36 The MRC dyspnea
scale concerns perceived breathlessness and consists of five
degrees: 1, ‘‘shortness of breath with strenuous exercise’’;
2, ‘‘shortness of breath when hurrying’’; 3, ‘‘walking slower
than people of the same age on the level ground or stop for
breath while walking at own pace on the level ground’’; 4,
‘‘needing to stop after 100 yards on the level ground’’; 5,
‘‘too breathless to leave the house’’. A Spanish translation
of MRC dyspnea scale was administered to the subjects.37
Health-related quality of life
All patients were administered the Short Form 12 Health
Survey Questionnaire (SF-12), an abbreviated version of the
SF-36 health questionnaire that contains 12 items.38 These
12 items explain more than 90% of the variance of the
physical and mental component scales of the SF-36. From
them two scores can be calculated, the physical (PCS-12)
component summary and the mental (MCS-12) component
summary, using a value of 50 with a standard deviation of
10 as reference population. In this study, the general
Spanish adult population has been used as a reference.39,40
Scores range from 0 to 100, with higher scores representing
better HRQL. A score> 60 has been regarded as high HRQL,
40e60 as normal HRQL, and <40 as impaired (low) HRQL. A
translated version of the questionnaire validated for Spain
has been used.41
Statistical analysis
In order to detect a clinically relevant difference of 5 points
in the mean PCS-12 and MCS-12 scores among the subgroups
of men and women stratified by the three severity levels of
COPD with a statistical power of 95% and a level of statis-
tical significance (alpha) of 0.05, using a two-tailed Stu-
dent’s t-test for the comparison of two groups (considering
a standard deviation of 12 for the mean SF-12 scores of
each group), a total number of patients required in each
stratum was 165. According to the data of the IBERPOC
Study,42,43 women showed the lowest prevalence of COPD
(22%) with a subset of women with severe diseaseaccounting for 1.653% of the total number of patients with
COPD. Therefore, the total number of patients required
was 9981 (165/0.01653). This number was increased to
12,477 assuming a percentage of losses of 20% due to non-
evaluable cases.
Of the total number of COPD patients of both the sexes
recruited, the subset of women with COPD was selected for
the study. Women were distributed into 15 subgroups as
follows: for each severity level of COPD (mild, moderate,
severe), patients corresponding to five age strata (40e49
years, 50e59 years, 60e69 years, 70e79 years, and >80
years) were selected. Therefore, mild, moderate and
severe COPD subgroups included the five age strata each.
Then, the same number of men than the total number of
women in each subgroup was selected at random. Finally,
1661 pairs were obtained.
The Statistical Package for the Social Sciences (SPSS,
version 12.0) was used for the analysis of data. Double data
entry was carried out with a subsequent validation to
guarantee the quality and consistency of the data.
Continuous variables are expressed as mean and standard
deviation (SD) or median and ranges (25e75th percentiles).
Qualitative variables are described as frequency and
percentages. Confidence intervals (CIs) were calculated at
the 95% level. Differences in HRQL in the subgroups of
patients according to gender and severity of COPD were
analyzed with the paired Student’s t-test. The Spearman’s
rank-order correlation coefficient (r) was calculated to
assess the relationship between HRQL and FEV1 and level of
dyspnea. The chi-square (c2) test was used to assess the
differences in health resources utilization among the study
groups. Statistical significance was set at P 0.05.
Results
Women with COPD
A total of 1786 women with COPD, with a mean ( SD) age of
66.5 11.0 years, were included in theMUVICE cohort. They
accounted for 20.3% of 9405 COPD patients recruited by
1826 general practitioners and 240 pneumologists partici-
pating in the study. Sociodemographic and clinical charac-
teristics are shown in Table 1. Salient features were as
follows: 62.1% of patients were found in the 60e79-year
stratum, 73.5% had a BMI 25 kg/m2, 57.3% were never
smokers, 26.7% ex-smokers (median of 7 years since smoking
cessation), and 16.1% current smokers (median pack-years
30) who had been smoking for a mean of 30 12.3 years.
Patients had a long-standing COPD, with a mean time since
diagnosis of 9.5 years. With rear to the last spirometric
measurement, the mean FEV1 predicted value was
58.5 13.9%. The severity of COPD was mild or moderate in
89.3% of cases and severe in 10.7%. Half of the patients had
a moderate degree of dyspnea (MRC category 2). The
severity of COPD increased with age, with 34% of patients
aged 40e49 years suffering from moderate or severe COPD
as opposed to 66.3% of patients of 80 years or older
(P< 0.0001). The degree of dyspnea also increased with
age, with 4.4% of patients aged 40e49 years in the MRC
categories 4 and 5 compared with 30% of patients aged 80
years or older (P< 0.0001).
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and 44.1 11.8, respectively. General health and physical
functioning domains were those with the lowest scores,
whereas role emotional and social functioning domains
were those with the highest scores (Table 2). According to
the results of the SF-12 questionnaire, HRQL was graded as
normal (40e60 points) by 51.3% of patients and as low (<40
points) by 48.7% of patients. However, a higher percentage
of patients scored less than 40 points in the physical health
domain compared with the mental health domain (62% vs.
36.7%) (Table 2). As compared to the reference population,
patients with COPD had a reduction of HRQL, with a meanTable 1 Sociodemographic and clinical data of 1786 women wi
Characteristic N
Age, years (nZ 1727)
Age groups (nZ 1727)
40e49 Years
50e59 Years
60e69 Years
70e79 Years
80 Years
Height, cm, mean (SD) (nZ 1744)
Weight, kg, mean (SD) (nZ 1722)
Body mass index (BMI) (nZ 1704)
<25 kg/m2
25e29 kg/m2
30e34 kg/m2
35e39 kg/m2
40 kg/m2
Smoking (nZ 1769)
Never 1
Ex-smoker
Current smoker
Pack-years (nZ 216)
Years since COPD diagnosis (nZ 1312)
FEV1% predicted (nZ 1299)
FEV1/FVC% (nZ 1000)
Severity of COPD (nZ 1719)
Mild
Moderate
Severe
MRC dyspnea scale (nZ 1753)
1
2
3
4
5
a Twenty-fifth to Seventy-fifth percentile.of 1.4 1.1 for PCS-12 and 0.6 1.2 for MCS-12. The
percentage of women with low HRQL increased according
to age (31.9% for the 40e49-year age group compared with
62.6% for the 80-year age group, P< 0.0001), whereas the
percentage of women with high or normal HRQL decreased
significantly (68.1% vs. 37.4%, P< 0.0001). These differ-
ences remained statistically significant for PCS-12 but not
for MCS-12 (Fig. 1). Scores for the different domains of PCS-
12 and MCS-12 according to age are shown in Table 3.
In relation to COPD severity, PCS-12 was rated lower
than the MCS-12, that is, more women rated HRQL as low in
the physical component than in the mental componentth COPD (MUVICE cohort).
umber (%) Mean SD (range)a
66.5 11.0 (59e75)
135 (7.8)
314 (18.2)
529 (30.6)
543 (31.4)
206 (11.9)
159.8 7.3 (155e165)
71.0 11.7 (63e78)
27.9 4.7 (24.8e30.4)
452 (26.5)
791 (46.4)
330 (19.4)
102 (5.9)
29 (1.7)
013 (57.3)
472 (26.7)
284 (16.1)
33.8 17.5 (20e45)
9.5 8.1 (4e13)
58.5 13.9 (49e70)
64.4 14.3 (55.5e73)
754 (43.9)
781 (45.4)
184 (10.7)
302 (17.2)
812 (46.3)
398 (22.7)
189 (10.8)
52 (2.9)
010
20
30
40
50
60
70
80
90
100
40-49 yrs 50-59 yrs 60-69 yrs 70-79 yrs >80 yrs
40-49 yrs 50-59 yrs 60-69 yrs 70-79 yrs >80 yrs
0
10
20
30
40
50
60
70
80
90
100
Low
Normal
High
Low
Normal
High
Figure 1 Differences in HRQL according to age. Changes
were statistically significant (P< 0.0001) for the physical
component of the SF-12 (upper panel) but not for the mental
component (lower panel).
Table 2 Quality of life in 1786 women with COPD (MUVICE
cohort).
SF-12 questionnaire Mean SD No. of
patients (%)
Physical component summary
(PCS-12)
36.5 10.3
Mental component summary
(MCS-12)
44.1 11.8
SF-12 scales
Physical functioning 37.4 31.7
Role physical 40.1 45.1
Bodily pain 58.6 29.8
General health 30.6 19.9
Vitality 40.7 25.7
Social functioning 61.8 26.5
Emotional role 62.0 45.4
Mental health 58.5 20.5
Physical domain (nZ 1786)
High (>60 points) 4 (0.2)
Normal (40e60 points) 675 (37.8)
Low (<40 points) 1107 (62.0)
Mental domain (nZ 1786)
High (>60 points) 73 (4.0)
Normal (40e60 points) 1057 (59.2)
Low (<40 points) 656 (36.7)
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with mild disease, 33.9 9.4 in those with moderate COPD
and 28.5 8.3 in those with severe disease (P< 0.001); the
corresponding figures for the mean MCS-12 scores were
45.8 11.4, 43.5 11.6 and 39.9 12.6 in the groups of
mild, moderate and severe COPDs, respectively
(P< 0.0001). There were statistically significant differ-
ences according to the severity of the disease in the mean
scores of all domains of the PCS-12 and MCS-12 scales
(Table 3). Moreover, patients with severe COPD showed
a significantly higher (P< 0.0001) reduction of HRQL for
both the physical (2.3 0.9) and mental domains
(1.1 1.3) than patients with moderate or mild COPD as
compared with the reference population.
HRQL correlated significantly with FEV1 in both PCS-12
(rZ 0.327, P< 0.0001) and MCS-12 (rZ 0.132, P< 0.0001)
scales. As expected, an inverse significant correlation
between HRQL and degree of dyspnea in the PCS-12
(rZ0.563, P< 0.0001) and the MCS-12 (rZ0.247,
P< 0.0001) scales was observed.
Men and women with COPD matched by age and
severity level
In the subset of 1661 patients matched by age and COPD
severity, the median age of the patients was 68 years. As
shown in Table 4, there were statistically significant differ-
ences in anthropometric data and smoking history. In
general, women were thinner than men. Grade 1 overweight(BMI 25e29 kg/m2) was recorded in 46% of women and in 56%
of men (P< 0.0001). Women had also a significantly worse
HRQL than men in all physical and mental domains.
A significantly higher percentage of women considered that
HRQL was low as compared with men (Fig. 3). The use of
health care resources was similar in both the genders (Table
4), although a significantly higher percentage of women
visited their family physicians (non-programmed visits) in
the previous 12 months than men. The mean length of
hospitalization for COPD exacerbation was significantly
greater in men (3.5 2.6 days) than in women (2.9 2.4
days) (PZ 0.02). Differences in other variables were not
observed. Smoking cessation counseling and stop smoking
treatment were significantly more often received by men.
Pulmonary rehabilitation was more frequently used by
women than men. The use of different pharmacological
treatments was similar in both the genders, although men
used bronchodilators and long-acting anticholinergics more
frequently than women, and women received oral steroids
more often than men (Table 4).
Discussion
This study was conducted to assess the clinical character-
istics of COPD and the impact of the disease on HRQL in
a large population of Spanish women with COPD during the
Table 3 Differences in HRQL according to age and severity of level in 1786 women with COPD (MUVICE cohort).
Physical component Mental component
Physical
functioning
Role
physical
Bodily
pain
General
health
Vitality Social
functioning
Emotional
role
Mental
health
Age groups, years
40e49 (nZ 135) 57.8 (30.9) 58.9 (44.8) 71.5 (26.8) 39.1 (21.9) 50.1 (25.7) 74.1 (21.7) 69.3 (42.8) 63.3 (21.0)
50e59 (nZ 314) 45.8 (30.3) 45.5 (45.7) 67.7 (27.8) 34.6 (19.1) 45.9 (24.6) 68.7 (24.5) 61.9 (44.8) 60.3 (20.9)
60e69 (nZ 529) 39.0 (30.2) 42.8 (43.5) 59.7 (27.7) 31.3 (17.9) 42.7 (25.2) 63.5 (24.7) 63.8 (44.8) 59.5 (19.7)
70e79 (nZ 543) 32.4 (31.3) 34.2 (43.5) 53.6 (30.9) 27.6 (20.0) 37.1 (25.2) 57.6 (27.5) 54.9 (46.4) 56.4 (20.4)
80 (nZ 206) 19.4 (26.7) 28.2 (42.3) 45.1 (28.4) 24.0 (20.3) 30.5 (25.0) 49.4 (27.9) 57.0 (47.2) 56.0 (21.0)
COD severity
Mild (nZ 754) 50.9 (30.5) 56.6 (44.9) 68.0 (27.1) 38.6 (19.4) 47.5 (25.6) 70.3 (24.6) 68.8 (43.0) 63.4 (20.5)
Moderate (nZ 781) 30.8 (28.8) 30.5 (42.2) 52.8 (28.6) 26.6 (17.5) 37.4 (23.7) 57.4 (24.3) 59.5 (46.2) 56.1 (19.0)
Severe (nZ 184) 10.2 (21.1) 12.0 (29.0) 46.1 (33.8) 14.1 (17.1) 27.5 (26.6) 44.3 (29.9) 46.7 (45.8) 49.4 (22.0)
Data as mean (standard deviation, SD); P< 0.0001 for the comparisons across year strata in all domains except for emotional role;
P< 0.0001 for the comparisons across levels of COPD severity in all domains.
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of women was drawn from a previous study (the VICE Study)
in which data of 9405 patients with COPD were analyzed.44
The present study describes the clinical profile of COPD in
women and adds evidence of gender-related differences in
two groups of 1661 men and women with COPD matched by
severity of COPD as measured by FEV1 and age. To our0
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Figure 2 Across all COPD severity stages, more women rated
their HRQL as low for the physical component (upper panel)
than for the mental component (lower panel).knowledge, this is the largest clinical series of matched
men and women with COPD reported up to now. In this
respect, our main findings of a worse HRQL for women in all
domains of the SF-12 questionnaire as compared with men
are consistent with previous studies of de Torres et al.17,33
using the disease-specific SGRQ instrument.
With regard to anthropometric variables, in our study,
like others,17,45 BMI values in women were lower than in
men, suggesting that COPD may affect the nutritional
status in a different way, with women appearing more
susceptible to the effect of the disease. Men and women
showed a mean duration of COPD of 9 years since diagnosis.
Other lung function parameters and degree of dyspnea
were similar in both the genders. The severity of COPD and
the severity of dyspnea increased with age; 66% of women
in the youngest age stratum (40e49 years) had mild COPD
and, therefore, suitable candidates for effective thera-
peutic intervention.
Interestingly, the percentage of never smokers among
women was very high (57% of cases), whereas only 6% of
men never smoked. Other studies have also shown that
women smoked less than men,17,33,46 although differences
in the current smoking status were not observed.33 Non-
smoking-related COPD is diagnosed in 5e12% of patients,
and most frequently in women.13 Moreover, there may also
be underdiagnosis and misdiagnosis of COPD in both the
sexes because objective measures of lung function are
underused.9,44 In our study, different reasons may account
for the high number of women with COPD who never
smoked, including the effect of passive smoking and COPD
misdiagnosis. On the other hand, patients with long-
standing asthma may develop chronic airflow obstruction
showing spirometric lung function measurements sugges-
tive of COPD. As has been reported, having asthma
increases 17 times the risk of receiving a diagnosis of
emphysema and 12.5 times the risk of fulfilling COPD
criteria.47 We also found that 26% of men and 16% of women
continued smoking. Although these percentages are lower
than the percentage of current smokers of 35% both in men
and women reported in a previous cross-sectional survey of
11,973 outpatients with COPD carried out in Spain,48 efforts
Table 4 Differences in the clinical characteristics, HRQL, health care resources utilization and treatment between men and
women matched by age and COPD severity.
Characteristic Men (nZ 1635) Women (nZ 1640) P value
Height, cm 168.0 7.0 159.8 7.4 <0.0001
Weight, kg 77.6 11.4 70.9 11.8 <0.0001
Body mass index (BMI), kg/m2 27.5 3.7 27.9 4.7 0.021
Smoking, no. of patients (%) <0.0001
Never 101 (6.1) 942 (57.2%)
Ex-smoker 1123 (67.9) 442 (26.8)
Current smoker 431 (26.0) 264 (16.0)
Pack-years 38.6 17.9 33.9 17.6 0.003
Duration of smoking, years 35.6 13.9 29.9 12.1 0.003
Years since smoking cessation 10.6 8.3 8.3 7.1 0.020
Years since COPD diagnosis 9.2 7.5 9.1 8.1 0.956
FEV1% predicted 57.9 13.5 58.4 14.0 0.603
FEV1/FVC% 63.0 14.1 64.4 14.3 0.283
MRC dyspnea scale, no. of patients (%) 0.061
1 297 (18.2) 289 (17.7)
2 769 (47.0) 748 (45.9)
3 403 (24.6) 370 (22.7)
4 132 (8.0) 171 (10.5)
5 34 (2.0) 51 (3.1)
Health-related quality of life (SF-12)
Total score 43.5 7.6 40.3 8.1 <0.0001
Physical component summary (PCS-12) 38.3 10.4 36.5 10.4 <0.0001
Physical functioning 43.7 32.4 37.3 31.7 <0.0001
Role physical 50.7 46.3 40.0 45.0 <0.0001
Bodily pain 68.1 27.8 58.6 29.7 <0.0001
General health 33.6 19.2 30.4 19.9 <0.0001
Mental component summary (MCS-12) 48.7 10.3 44.1 11.8 <0.0001
Vitality 47.0 26.8 40.6 25.7 <0.0001
Emotional role 78.4 38.3 61.9 45.4 <0.0001
Mental health 66.1 19.6 58.6 20.5 <0.0001
Use of health care resources, no. of patients (%)
Non-programmed visits to the family physician 1085 (65.3) 1168 (70.3) 0.002
Non-programmed visits to the pneumologist 576 (34.7) 604 (36.4) 0.304
Emergency department consultations 644 (38.8) 681 (41.0) 0.178
Hospital admissions 343 (20.7) 324 (19.5) 0.388
Sick leave 157 (9.4) 145 (8.7) 0.442
Non-pharmacological treatment, no. of patients (%) 810 (48.8) 719 (43.3) 0.003
Smoking cessation counseling 462 (27.8) 271 (16.3) <0.0001
Stop smoking treatment 79 (4.7) 43 (2.5) 0.0009
Oxygen therapy 116 (6.9) 111 (6.6) 0.717
Rehabilitation 139 (8.3) 190 (11.4) 0.002
Pharmacologic treatment, no. of patients (%) 1400 (84.3) 1393 (83.9) 0.742
Bronchodilators 1221 (73.5) 1164 (70.1) 0.028
Short-acting b2 agonists 437 (26.3) 430 (25.9) 0.790
Long-acting b2 agonists 369 (22.2) 356 (21.4) 0.587
(continued on next page)
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Table 4 (continued)
Characteristic Men (nZ 1635) Women (nZ 1640) P value
Short-acting anticholinergics 245 (14.8) 265 (16.0) 0.332
Long-acting anticholinergics 713 (42.9) 615 (37.0) 0.0006
Theophylline 316 (19.0) 319 (19.2) 0.894
Fixed combinations 949 (57.1) 961 (57.9) 0.675
Oral steroids 95 (5.7) 147 (8.8) 0.0005
Inhaled steroids 273 (16.4) 249 (15.0) 0.242
Data as mean standard deviation unless otherwise stated.
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ventions directed to quit smoking seem to be of utmost
importance. Targeting smoking cessation programs in
women with COPD is necessary, not only because it has
been shown that women who smoke had greater difficulty
quitting than men,13,14 but also because smoking cessation
counseling and stop smoking treatment are significantly
more frequently offered to men than to their female
counterparts, as shown in our study.
The main objective of the study was to characterize
HRQL in women with COPD and to assess whether the
disease had a different impact on HRQL according to the
gender. A total of 48.7% of women considered that their
HRQL was low (62% for the physical component and 36.7%
for the mental component). In general, the physical health
domain was rated poorly than the mental health domain,
with physical functioning, general health, and role physical
showing the lower scores. Lower scores for the PCS-12
component than for the MCS-12 component in patients with
COPD have also been reported in other studies.30,32 Signif-
icant differences in HRQL according to age and COPD
severity were also observed, confirming the effect of age
and stage of disease on HRQL in patients with COPD. It has
been shown that COPD is the main cause of deterioration of
quality of life in elderly subjects and that the degree of this0% 20% 40% 60% 80% 100%
Men
(physical)
Women
(physical)
Men (mental)
Women
(mental)
Low
Normal
High
Figure 3 A higher percentage of women considered that
HRQL was low as compared with men for both the physical and
the mental components of the SF-12.impairment strongly depends on the decrease in FEV1.
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The present findings, however, should be interpreted taking
into account that the influences of other factors, such as
socioeconomic status, education level, working status, or
underlying comorbid diseases were not evaluated.
However, given that a large majority of women had mild to
moderate COPD, the observation of low scores in almost all
domains of the SF-12 questionnaire is clinically relevant,
suggesting that women with COPD may develop symptoms
influencing HRQL in the presence of relatively small degrees
of airway obstruction.
An interesting aspect of the study was the comparison of
HRQL among pairs of men and women with COPD matched
by age and severity of disease as measured by the FEV1.
Compared with men, women had significantly lower scores
in the total score of the SF-12 questionnaire as well as in all
physical and mental domains. Our results are in agreement
with those previously reported by de Torres and
colleagues17,33 in two matched case series studies. In the
study of Antonelli-Incalzi et al.49 in which differences in
health status according to the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) criteria were evaluated,
females had greater susceptibility to the negative effects
of COPD on HRQL measured by the SGRQ and generic
indexes of health status.
In relation to the utilization of health care resources,
the only statistically significant difference between men
and women was a higher percentage of women requesting
non-programmed visits to their general practitioner. As
previously mentioned, non-pharmacological treatment was
more frequently used in men than in women, particularly
smoking cessation counseling and treatment to quit
smoking. Pulmonary rehabilitation, however, was more
often used by women. Differences in pharmacological
treatment for COPD were only significant for bronchodila-
tors and long-acting anticholinergics, which were more
frequently used by men, and for oral steroids, which were
used more often by women.
In the present study COPD was defined as a ratio of FEV1/
FVC< 0.7 after bronchodilation. It is possible that the
number of elderly patients (above 60 years) with COPD may
be overestimated.50 On the other hand, the present results
should be interpreted taking into account some limitations
of the study. Firstly, a generic questionnaire was used to
measure HRQL, which is less sensitive than the specific
tools (e.g., SGRQ), although the SF-12 instrument contains
only 12 items and is easy to administer in ambulatory
patients with COPD who were mostly attended in primary
care centers. Secondly, the cross-sectional design of the
Quality of life in women with COPD 1311study limits the ability to describe trends and changes in
HRQL in relation to progression of the disease. However,
data recorded were obtained in a non-trial setting, which
enhances the external validity of the study. Thirdly, a high
percentage of women were never smokers. These patients
were not excluded because the objective of the study was
to analyze HRQL in outpatients with COPD who were
attended by general practitioners and pneumologists in the
real world setting. Nevertheless, a diagnosis other than
COPD cannot be definitively excluded. Finally, other factors
that may affect HRQL (e.g., socioeconomic status, educa-
tion, comorbidities) were not assessed. In contrast, the
large sample size of both the cohort of women and the pairs
of men and women matched by age and COPD severity
strengthens the findings of the present survey.
We conclude that in the present population of women
with COPD who were attended in the outpatient setting in
daily practice conditions, HRQL was impaired especially the
physical component of the SF-12 instrument. Moreover, for
the same age and severity of COPD, women showed
significantly lower scores in all domains of the SF-12 than
men. According to these results more attention should be
given to the deleterious effect of chronic airway obstruc-
tion on HRQL in women with COPD even in those with mild
stages of the disease.
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